Loading clinical trials...
Loading clinical trials...
Screening Protocol to Evaluate Acid Alpha Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease for Potential Inclusion in Future Clinical Studies With Myozyme (Alglucosidase Alfa)
Pompe disease (also known as glycogen storage disease type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. The primary objective of this study is to identify potential candidates for future clinical studies in Pompe disease.
Age
8 - No limit years
Sex
ALL
Healthy Volunteers
No
Tower Hematology/Oncology Medical Group
Beverly Hills, California, United States
Children's National Medical Center
Washington D.C., District of Columbia, United States
Washington University Medical Center
St Louis, Missouri, United States
Mount Sinai School of Medicine
New York, New York, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Start Date
May 1, 2005
Completion Date
October 1, 2005
Last Updated
May 5, 2015
60
Estimated participants
Lead Sponsor
Genzyme, a Sanofi Company
NCT06121011
NCT01665326
NCT06109948
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions